- Home
- Companies
- czech republic
- inflammatory diseases
Show results for
Refine by
Inflammatory Diseases Suppliers Serving Czech Republic
65 companies found
based inFreiburg, GERMANY
Dermagnostix, a spin-off company, emerged from the collaborative efforts of the Hahn-Schickard Institut, the Helmholtz Zentrum München, and TU Munich, leveraging decades of sophisticated research in dermatology, immunology, bioinformatics, and ...
Dermagnostix introduces the PsorX-LabDisk, a cutting-edge molecular diagnostic tool that significantly enhances the accuracy of diagnosing psoriasis and eczema. Distinct from traditional subjective methods, which often lead to misdiagnosis due to ...
based inBoldon Colliery, UNITED KINGDOM
Immunodiagnostic Systems Holdings Ltd (hereafter referred to as IDS) is a leading in vitro diagnostic solution provider to the clinical laboratory market. We develop, manufacture and market innovative immunoassays and automated immunoanalyser ...
i-Tracker anti-Adalimumab is an automated assay intended for the quantitative measurement of anti-Adalimumab antibodies (anti-drug antibodies: ADAb) in human serum or plasma ...
based in, NEW JERSEY (USA)
Founded in 2013 by a group of passionate synthetic biologists with decades of industry experience and a proven track record of delivering cost-effective DNA solutions, Synbio Technologies is incorporated with a single mission in mind: to empower ...
In recent years, the proportion of biological drugs in the global pharmaceutical market has been close to 20%. The focus within the global pharmaceutical market has been gradually shifting from small molecule chemical drugs to biomacromolecules ...
based inBasel, SWITZERLAND
EsoCap’s vision is to improve the lives of patients affected by esophageal diseases. The esophagus is a particularly challenging environment, as swallowed drugs only remain in the area between the mouth and the stomach for a few seconds. EsoCap, a ...
EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for targeted and long-lasting treatment of diseases of the upper gastrointestinal tract for the first ...
based inIrvine, CALIFORNIA (USA)
We are a global biomedical technology company that offers advanced in-vitro diagnostic solutions. We develop, patent, manufacture and market IVD products. Our primary research and development focus is on gastrointestinal and inflammatory diseases ...
based inMiami, FLORIDA (USA)
Veru is a biotechnology company focused on developing novel medicines for COVID-19, additional ARDS-related diseases, and for breast and prostate cancers. Veru is a Wisconsin corporation and is the successor to The Wisconsin Pharmacal Company, Inc. ...
based inSt. Paul, MINNESOTA (USA)
EPIEN Medical continues to develop its innovative, patented platform for nonbiologic, therapeutic treatments to restore and regenerate impaired epidermal and dermal tissue. EPIEN Medical, Inc. (EMI) is a privately held biomedical company ...
Indicated for use as an adjunctive rinse in the tooth root canal and on adjacent tooth surfaces to enhance the removal of post-instrumentation dentinal debris and smear ...
based inDijon, FRANCE
Oncodesign is a biopharmaceutical company that offers you powerful technologies and tools to guide you through the development of your drug, from medicinal chemistry to drug candidate. Our therapeutic areas are expanding. In addition to oncology, ...
Establishing proof of concept in preclinical pharmacology is a critical step in the drug discovery process. This is one of the decisive factors in setting the therapeutic indication(s) targeted in clinical models and in the decision to continue a ...
based inCambridge, MASSACHUSETTS (USA)
We are a group of individuals who know that there is a better way to develop drugs. Our business model and broad, science-based portfolio has attracted some of the brightest minds in drug development. Our team brings together more than 300 years of ...
BOS-475 potently inhibits multiple clinically validated pathways (IL-12/IL-23-p40, Th17 cytokines and TNF) relevant to psoriasis pathophysiology. BOS-475 demonstrates broad inhibitory activities on other key disease-relevant ...
based inParma (PR), ITALY
We develop and patent state-of-the-art systems at the service of the health professions. FRAS (Free Radical Analytical System) is the most widely used system for measuring Oxidative Stress. Today, our tests are present in more than 60 countries ...
Saliva has remarkable antioxidant properties that are preparatory to many of its protective functions. MINISAT is a photometer dedicated to monitoring the antioxidant power of saliva ...
based inBasel, SWITZERLAND
Aurealis Therapeutics, a Swiss-Finnish private biopharmaceutical company, is now entering the clinical trial phase with its patented three-in-one combination product AUP-16 for chronic non-healing wounds and other regenerative diseases. The ...
based inSarasota, FLORIDA (USA)
Lumos Diagnostics specializes in rapid, cost-effective and complete point-of-care (POC) diagnostic test solutions to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and ...
based inHergiswil, SWITZERLAND
BioLingus is a Swiss biotech company spearheading the development of oral (sublingual) delivery of peptides and proteins for chronic diseases and immuno-therapy via our innovative formulation technology. Our company focuses on the development of ...
based inZüric, SWEDEN
Bee venom powder is produced by honey bees and the most common uses for bee venom are in cosmetics, but also in research, pharmaceuticals and other applications. For example, bee venom powder is used for allergy treatment for people that are ...
based inMainz, GERMANY
Fuelled by Innovation: With a pioneering spirit and high technical expertise, ORGENTEC has become firmly established in medical diagnostics. Our employees’ talent and skills establish the basis for our success. At our headquarters in Mainz, Germany, ...
It is used for the differentiation of a positive pANCA immunofluorescence result. Cathepsin G antibodies are found in cases of systemic vasculitis, inflammatory rheumatic diseases (SLE, Sjögren’s ...
based inLausanne, SWITZERLAND
AB2 Bio Ltd., located at the Innovation Park of the École Polytechnique Fédérale de Lausanne (EPFL), is a drug discovery and development company focused on developing “best in class” innovative therapies for the treatment of inflammatory diseases ...
Tadekinig alfa is a recombinant Interleukin-18 Binding Protein (r-hIL-18BP) with a high affinity for IL-18, a major inflammatory cytokine. In healthy people, there is a large excess of naturally occurring IL-18BP keeping levels of ...
based inNeihu Dist, TAIWAN
Pharmigene is established in 2005 and funded by venture capital firms and individuals. Our goal is to innovate and commercialize diagnostic tests that enable individuals to be better informed about their genomic makeup and to make decisions that ...
based inStockholm, SWEDEN
IBT is a pharmaceutical company with its registered office in Stockholm with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. IBT is currently developing its ...
IBP-9414 for the prevention of necrotizing enterocolitis (NEC) contains the active substance Lactobacillus reuteri, which is a co-evolved human bacterial strain naturally present in breast milk. Lactobacillus reuteri is a live bacteria known to be ...
based inHerk-de-Stad, BELGIUM
Mona Lisa N.V., a member of the EurimPharm group, has been manufacturer of medical devices for more than 30 years. It is specialized on medical devices class II and III for the field of gynecology. The business fields of Mona Lisa N.V. encompass: ...
This Mona Lisa model has the same design as the "Nova T 380". Also this model requires preloading before insertion. In contrast to the CuT 380A version, the horizontal arms are to be pulled into the ...
based inMechelen, BELGIUM
Galapagos discovers, develops and commercializes small molecule medicines with novel modes of action. Our pipeline comprises discovery through to Phase 3 programs in inflammation, fibrosis, and other indications. Our first medicine is approved and ...
These molecules inhibit the different members of the SIK family and have shown the potential to modulate anti-inflammatory cytokines and pro-inflammatory cytokines. Targeted and selective inhibition of SIK proteins ...